Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide in Metastatic Pheochromocytoma or Paraganglioma
NCT05858177Phase 2Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2019
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in pheochromocytoma and Paraganglioma (PGL), sponsored by Peking Union Medical College Hospital. Primary endpoints: Disease Control Rate at Cycle 3 and Objective Response Rate at Cycle 3. Started Oct 2019; status: completed.
02
Drugs
temozolomide
03
Conditions
pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT05858177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05858177.